van de Weijer, T. http://orcid.org/0000-0003-3485-7881
Bemer, F.
de Vos-Geelen, J. http://orcid.org/0000-0003-2578-1766
Hermans, B. http://orcid.org/0000-0003-4831-3690
Mitea, C. http://orcid.org/0000-0001-5885-957X
van der Pol, J. A. J. http://orcid.org/0000-0002-5698-3849
Lodewick, T. http://orcid.org/0000-0001-5388-1575
Wildberger, J. E. http://orcid.org/0000-0002-4810-6854
Mottaghy, F. M. http://orcid.org/0000-0002-7212-6521
Funding for this research was provided by:
Universitätsklinikum RWTH Aachen
Article History
Received: 6 December 2023
Accepted: 15 February 2024
First Online: 26 February 2024
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Patients signed informed consent regarding publishing their data (METC-number 2021–2992). The study was approved by the Medical Ethical Committee of Maastricht University Medical Center according to the declaration of Helsinki and registered under METC-number 2021–2992.
: FMM is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis; holds speaker positions at Siemens, GE Healthcare, and Bayer; and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision Healthcare LLC. FMM is an editor of EJNMMI. The other authors have no relevant financial or non-financial interests to disclose.